Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ersodetug (RZ358) / Rezolute
sunRIZE, NCT06208215: RZ358 Treatment for Congenital Hyperinsulinism	Recruiting	3	56	Europe, Canada, US, RoW	RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC	Rezolute	Congenital Hyperinsulinism	04/25	09/26
NCT06881992: A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism	Recruiting	3	48	US	Ersodetug, Placebo	Rezolute	Tumor- Associated Hyperinsulinism	09/27	09/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ersodetug (RZ358) / Rezolute
sunRIZE, NCT06208215: RZ358 Treatment for Congenital Hyperinsulinism	Recruiting	3	56	Europe, Canada, US, RoW	RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC	Rezolute	Congenital Hyperinsulinism	04/25	09/26
NCT06881992: A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism	Recruiting	3	48	US	Ersodetug, Placebo	Rezolute	Tumor- Associated Hyperinsulinism	09/27	09/27